March 05, 2026 — 57 articles reviewed
This cycle’s coverage centered on reassuring longitudinal data about cannabis and cognitive aging in older adults, mounting evidence that THC blood levels are poor proxies for driving impairment, and persistent access failures for some of the most vulnerable patient populations in the U.S. and U.K. Alongside these clinical themes, significant regulatory and industry developments signaled shifting ground at the federal level and across international markets.
The through-line across this entire cycle is the distance between what the evidence supports and what systems actually allow, whether that is an older adult denied a safe medicine over unfounded dementia fears, a child seizing because funding did not follow the law, or a dying patient forced to leave the hospital to access relief. Our job as clinicians is to close that gap, one patient and one honest conversation at a time.
Digest-Level Clinical Commentary
Clinical Reflection
The emerging longitudinal data on cannabis and cognitive aging in older adults represents a meaningful shift in our evidence base, moving us away from categorical warnings toward more nuanced risk stratification in this population. Combined with evolving federal regulatory signals, we’re entering a phase where evidence-based cannabis medicine practice can move beyond anecdotal observation toward standardized dosing protocols and clear patient selection criteria. This convergence of clinical data and regulatory movement should prompt us to develop more rigorous screening tools and monitoring frameworks for older adult patients seeking cannabis for pain, sleep, and other age-related conditions.
Clinical Perspective
Recent longitudinal data on cannabis use and cognitive aging in older adults appear to provide reassurance regarding previously expressed concerns about cognitive decline, suggesting that effects may be less pronounced or more nuanced than earlier cross-sectional studies indicated. The growing body of evidence on THC’s mechanisms, combined with ongoing regulatory evolution at the federal level, is beginning to establish a more empirically grounded framework for clinical decision-making around cannabis use in aging populations. These developments warrant continued monitoring by clinicians as the evidence base matures and regulatory pathways clarify.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: